Nektar Therapeutics (NASDAQ:NKTR) headquartered in San Francisco, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 5:00 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.nektar.com
Earnings Expectation
Nektar Therapeutics is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, NKTR to report 3Q20 loss of $ 0.74 per share. For the full year, analysts anticipate top line of $ 147.90 million, while looking forward to loss of $ 2.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 140.00 million ~ $ 145.00 million
Click Here For More Historical Outlooks Of Nektar Therapeutics
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology.
